TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00294268

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive behavioural therapy
Description: 20 weekly sessions of CBT integrated with motivational enhancement strategies
Study: NCT03489447

Intervention type: OTHER
Intervention: ICU care
Description: exposure to ICU treatment with or without diagnosed sepsis

Intervention type: OTHER
Intervention: ICU care
Description: exposure to ICU treatment with or without diagnosed sepsis
Study: NCT04224649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARA Filler(Hyaluronic acid Filler)
Description: The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane® Lidocaine
Description: The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
Study: NCT02339571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT04185883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.
Study: NCT01749514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
Study: NCT04185883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: RMC-4630 administered orally as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: afatinib administered orally as a tablet.
Study: NCT04693273

Intervention type: OTHER
Intervention: Decision Aid for Surgical Modality Choice
Description: A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
Study: NCT01540630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802
Description: CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
Study: NCT04185883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, pemetrexed, docetaxel, paclitaxel
Description: Carboplatin, pemetrexed, docetaxel administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered as an IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVASI® (bevacizumab-awwb)
Description: MVASI® (bevacizumab-awwb) administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: TNO155 administered orally as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Chemotherapy (Regimen 1)
Description: Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Chemotherapy (Regimen 1)
Description: Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
Study: NCT01749514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
Study: NCT04185883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Chemotherapy (Regimen 2)
Description: IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: BI 1701963 administered orally
Study: NCT01749514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
Study: NCT04185883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus administered orally.
Study: NCT01540630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo comparator for 28 days.
Study: NCT03358433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT01183767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin-Gallate
Description: EGCG in a dosage of up to 10mg/kg body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00860236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psycoeducation/counseling
Description: 2 days of education on mechanisms of illness and coping strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: 4 days intensive training in understanding and behavioural changes
Study: NCT02334917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical wound closure with superficial absorbable sutures
Description: Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
Study: NCT02599207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sibling umbilical cord blood
Description: All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
Study: NCT03628313

Intervention type: OTHER
Intervention: Transthoracic ultrasound
Description: Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
Study: NCT04150666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydration
Description: the same with arm descriptions
Study: NCT00984165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single fraction radiation
Description: 8-Gy fraction of radiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single fraction radiation
Description: 8-Gy fraction of radiation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Unmanipulated Donor Lymphocyte Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Unmanipulated Donor Lymphocyte Infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
Study: NCT04030546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine capsule
Study: NCT01242696

Intervention type: PROCEDURE
Intervention: Coronary artery stenting
Description: Coronary artery stenting with drug eluting stents
Study: NCT03695627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute a day, 8 week digital meditation
Study: NCT00798629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell-adenovirus CCL21 vaccine
Description: Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
Study: NCT04147390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescribe topical 0.03 % tacrolimus
Description: prescribe topical 0.03 % tacrolimus 3 times a day for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescribe mycophenolate mofetil(MMF)
Description: MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
Study: NCT02533427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily
Study: NCT05750043

Intervention type: DRUG
Intervention: bi-annual CDTI
Description: bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention
Study: NCT03608293

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Broncho Alveolar Lavages (BAL)
Description: BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Broncho Alveolar Lavages (BAL)
Description: BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
Study: NCT02533427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate/ethinyl estradiol
Description: Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
Study: NCT03998189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Collection
Description: Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Collection
Description: Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Collection
Description: Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Collection
Description: Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine Collection
Description: Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine Collection
Description: Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor Collection
Description: During surgical tumor removal, a tumor tissue sample will be collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor Collection
Description: During surgical tumor removal, a tumor tissue sample will be collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical History Data Collection
Description: Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical History Data Collection
Description: Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
Study: NCT03846011

Intervention type: OTHER
Intervention: 24-h urine collection
Description: Collecting 24-h urine prior and after stone removal surgery
Study: NCT02657174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser in auricular acupuncture points
Description: 40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low level laser device off in auricular acupuncture points
Description: 40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
Study: NCT01324765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARGET
Description: 12-session group therapy twice weekly 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SGT
Description: 12 sessions supportive group therapy twice weekly 6 weeks
Study: NCT02736851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based telemedicine group
Description: All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period.
Study: NCT03274440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control group, not receiving THC or CBD.
Study: NCT02234089

Intervention type: DRUG
Intervention: Degarelix
Description: According to medical practice

Intervention type: DRUG
Intervention: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
Description: According to medical practice
Study: NCT02759471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A sphere lens (control)
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A asphere lens (test)
Description: contact lens
Study: NCT01125683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Capsule, oral single and multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Capsule, oral single and multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Capsule, oral single and multiple dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Capsule, oral and single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, oral and single dose
Study: NCT01442493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Methadone Treatment
Description: Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Treatment as usual
Description: Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
Study: NCT03362502

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PF-06939926
Description: Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels.
Study: NCT03853850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text messages
Description: From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
Study: NCT01781793

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Humidified room air (21% oxygen) will be inspired

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia
Description: 60% oxygen will be inspired
Study: NCT00678938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking abstinence oriented expert system intervention
Description: Participants received up to three counselling letters targeting smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking reduction oriented expert system intervention
Description: Participants received up to three counselling letters targeting smoking reduction